• Impact of vascular biology on cardiovascular disease, risk prevention, and treatment
Section IV - Update: RAAS manipulation and
cardiovascular risk--Hope for Peace?
The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.
Volume VI. This edition of the core curriculum is special, because it marks the 10th anniversary of the Vascular Biology Working Group. It covers basic science and clinical advances in vascular biology in a spectrum of disorders. The material is presented in five sections:
This slide/lecture program focuses on the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) trial, investigating the use of angiotensin-converting enzyme (ACE) inhibition in patients with stable coronary artery disease and normal left ventricular function. The goal is to provide greater understanding of the optimal clinical use of ACE inhibition for secondary prevention of cardiovascular disease in the daily practice of medicine.
The contents of this Curriculum Update feature the following topics:
- The renin-angiotensin-aldosterone system(RAAS) and its role in atherosclerosis
- The role of ACE inhibition in cardiovascular risk reduction
- Update on recent trial data
- ACC/AHA recommendations of the role of ACE inhibition for secondary prevention in patients with non-ST-segment elevation myocardial infarction and with ST-segment elevation myocardial infarction.
Download 04CoreRAASUpdateSect001.ppt (22 slides - 1.2MB)
Published by Medical Education Consultants, LLC (MEDCON), on behalf of the University of Florida College of Medicine.
The editorial content of this program does not necessarily reflect the views or recommendations of the University of Florida College of Medicine or AstraZeneca, King Pharmaceuticals Inc, Pfizer Inc, and Wyeth Pharmaceuticals, or the publisher. The reader is advised to consult the full prescribing information of each product prior to use.
This program was prepared and produced by Medical Education Consultants, LLC, Westport, Connecticut, on behalf of the University of
Florida College of Medicine through an unrestricted educational grant provided by AstraZeneca, King Pharmaceuticals Inc, Pfizer Inc, and Wyeth Pharmaceuticals.
©2004 Medical Education Consultants, LLC (MEDCON). All rights reserved.